|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-3-16
|
|
pubmed:abstractText |
Although most children with B-lineage acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma are cured, new agents are needed to overcome drug resistance and reduce toxicities of chemotherapy. We hypothesized that the novel anti-CD22 immunotoxin, RFB4(dsFv)-PE38 (BL22, CAT-3888), would be active and have limited nonspecific side effects in children with CD22-expressing hematologic malignancies. We conducted the first preclinical and phase I clinical studies of BL22 in that setting.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-10077166,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-10778980,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-11759074,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-11948105,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-12700949,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-12917300,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-14525789,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-14673054,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-14970517,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-15730852,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-16061911,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-16351633,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-17035650,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-17059365,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-17242396,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-18669463,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-18676854,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-18780861,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-18780868,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-19414673,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-19594633,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-2018837,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-2463099,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-699044,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-9292538,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20215554-9773870
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1894-903
|
|
pubmed:dateRevised |
2011-7-26
|
|
pubmed:meshHeading |
pubmed-meshheading:20215554-Adolescent,
pubmed-meshheading:20215554-Animals,
pubmed-meshheading:20215554-Antibodies,
pubmed-meshheading:20215554-Antigens, CD22,
pubmed-meshheading:20215554-Child,
pubmed-meshheading:20215554-Child, Preschool,
pubmed-meshheading:20215554-Enterotoxins,
pubmed-meshheading:20215554-Female,
pubmed-meshheading:20215554-Flow Cytometry,
pubmed-meshheading:20215554-Humans,
pubmed-meshheading:20215554-Immunoenzyme Techniques,
pubmed-meshheading:20215554-Immunoglobulin Fragments,
pubmed-meshheading:20215554-Immunotoxins,
pubmed-meshheading:20215554-Infant,
pubmed-meshheading:20215554-Lymphoma, Non-Hodgkin,
pubmed-meshheading:20215554-Maximum Tolerated Dose,
pubmed-meshheading:20215554-Mice,
pubmed-meshheading:20215554-Mice, SCID,
pubmed-meshheading:20215554-Precursor B-Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:20215554-Tissue Distribution,
pubmed-meshheading:20215554-Treatment Outcome,
pubmed-meshheading:20215554-Tumor Cells, Cultured,
pubmed-meshheading:20215554-Xenograft Model Antitumor Assays,
pubmed-meshheading:20215554-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
|
|
pubmed:affiliation |
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-1104, USA. waynea@mail.nih.gov
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I,
Research Support, N.I.H., Intramural
|
